• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Fat Tail Daily

Investment Ideas From the Edge of the Bell Curve

  • Menu
    • Commodities
      • Resources and Mining
      • Copper
      • Gold
      • Iron Ore
      • Lithium
      • Silver
      • Graphite
      • Rare Earths
    • Technology
      • AI
      • Bitcoin
      • Cryptocurrency
      • Energy
      • Financial Technology
      • Bio Technology
    • Market Analysis
      • Latest ASX News
      • Dividend Shares
      • ETFs
      • Stocks and Bonds
    • Macro
      • Australian Economy
      • Central Banks
      • World Markets
    • Small Caps
    • More
      • Investment Guides
      • Premium Research
      • Editors
      • About
      • Contact Us
  • Latest
  • Fat Tail Series
  • About Us
Market Analysis Latest ASX News

Creso Pharma Shares Up 20% as UN Eases Stance on Cannabis

Like 0

By Ryan Clarkson-Ledward, Thursday, 03 December 2020

Tiny pot stock Creso Pharma Ltd [ASX:CPH] is soaring today. The CPH share price is trading 22.22% higher at time of writing. A huge boost for investors as the market eyes up this fascinating stock....

Tiny pot stock Creso Pharma Ltd [ASX:CPH] is soaring today. The CPH share price is trading 22.22% higher at time of writing.

A huge boost for investors as the market eyes up this fascinating stock.

However, what is far more fascinating is the reason for Creso’s surge today. Rising higher on the back of a surprising and landmark decision from the UN…

Cannabis reclassified for good

As Creso notes, the UN has decided to reclassify cannabis. Removing it from the Schedule IV status that it has held since 1961.

Under Schedule IV, cannabis was treated as one of the most dangerous drugs. Sitting alongside other narcotics such as heroin. A severe judgement to say the least.

Now though, just over half a century later, the UN has turned a new leaf.

Cannabis will now move to Schedule I — the least restrictive schedule of the four. And while that still means the UN isn’t quite ready to remove it from the list entirely, it is a huge development. One that suggests the organisational body may finally be recognising cannabis’ medicinal potential.

For pot stocks like Creso, this is a huge sentimental win.

It proves yet again that the tide is continuing to turn. With more groups, governments, and individuals slowly realising the potential of this demonised drug. A drug that is rapidly cultivating a sizeable industry.

As Creso Director Boaz Wachtel notes:

‘The UN ruling to reclassify cannabis is a landmark decision and paves the way for the relaxing of cannabis drug classifications in large markets across the world.

‘The results of this vote follows 60 years of status quo, three years of scientific review by the world’s leading health organisations, two years of diplomatic discussions and considerable lobbying from NGOs.

‘I am proud and privileged to have been a part of a small group of dedicated activists that have fought for decades to reschedule cannabis. I am very confident that this decision will unlock a number of near term opportunities for Creso Pharma, and I look forward to working with the Board and management to unlock further value for shareholders.’

For shareholders that is certainly welcome news. As for how and when Wachtel hopes to ‘unlock’ this value though, remains to be seen.

After all, Creso investors have had a rough year. And now, more than ever, management needs to turn things around.

Hopefully this decision will help provide a catalyst for this goal.

What’s next for Creso?

The ongoing challenge for Creso is to continue to market and sell its established products. Largely revolving around a range of pharmaceutical and nutraceutical goods.

However, Creso also has cannabis-based products for cosmetics and animal wellbeing as well. So, they certainly have plenty of avenues to explore. It is simply a matter of seeing what sticks and what doesn’t.

With a little help from today’s exposure, they may be closer to making that happen.

Regards,

Ryan Clarkson-Ledward,
For Money Morning

PS: For more pot stock news, as well all things investing related, check out our daily e-letter Money Morning. Bringing you all the latest news that the mainstream isn’t fit to cover. Including insights to help you on your investing journey. For more info, and to sign up for free, click here.

All advice is general advice and has not taken into account your personal circumstances.

Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

Comments

Subscribe
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments
Ryan Clarkson-Ledward

Ryan’s Premium Subscriptions

Publication logo
Fat Tail Investment Research

Latest Articles

  • OpenAI and Microsoft Divorce?: Why this could be good for you
    By Charlie Ormond

    While breakups are rarely pretty, this one might actually benefit investors willing to look beyond the drama.

  • Three Lithium Stocks in the Buy Zone
    By Murray Dawes

    Lithium stocks jumped this week, so Murray and Callum discuss whether this could be the beginning of the second boom in lithium stocks. They also discuss a fund manager that is recovering and looking cheap

  • Every Australian Investor Has a Stake in Mining
    By James Cooper

    With its deep pool of retirement capital, Australia is on track to become the world’s primary destination for resource markets.

Primary Sidebar

Latest Articles

  • OpenAI and Microsoft Divorce?: Why this could be good for you
  • Three Lithium Stocks in the Buy Zone
  • Every Australian Investor Has a Stake in Mining
  • The next wave of AI winners
  • Could the US People Repudiate the National Debt?

Footer

Fat Tail Daily Logo
YouTube
Facebook
x (formally twitter)
LinkedIn

About

Investment ideas from the edge of the bell curve.

Go beyond conventional investing strategies with unique ideas and actionable opportunities. Our expert editors deliver conviction-led insights to guide your financial journey.

Quick Links

Subscribe

About

FAQ

Terms and Conditions

Financial Services Guide

Privacy Policy

Get in Touch

Contact Us

Email: support@fattail.com.au

Phone: 1300 667 481

All advice is general in nature and has not taken into account your personal circumstances. Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

The value of any investment and the income derived from it can go down as well as up. Never invest more than you can afford to lose and keep in mind the ultimate risk is that you can lose whatever you’ve invested. While useful for detecting patterns, the past is not a guide to future performance. Some figures contained in our reports are forecasts and may not be a reliable indicator of future results. Any actual or potential gains in these reports may not include taxes, brokerage commissions, or associated fees.

Fat Tail Logo

Fat Tail Daily is brought to you by the team at Fat Tail Investment Research

Copyright © 2025 Fat Tail Daily | ACN: 117 765 009 / ABN: 33 117 765 009 / ASFL: 323 988